212 related articles for article (PubMed ID: 26932346)
1. Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase.
Mukherjee S; Kalaycio M
Curr Hematol Malig Rep; 2016 Apr; 11(2):86-93. PubMed ID: 26932346
[TBL] [Abstract][Full Text] [Related]
2. [Management of advanced-phase chronic myeloid leukemia].
Kitanaka A
Rinsho Ketsueki; 2016; 57(10):1962-1971. PubMed ID: 27725594
[TBL] [Abstract][Full Text] [Related]
3. When to Consider Allogeneic Transplantation in CML.
Radich J
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S93-5. PubMed ID: 27521333
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.
Özen M; Üstün C; Öztürk B; Topçuoğlu P; Arat M; Gündüz M; Atilla E; Bolat G; Arslan Ö; Demirer T; Akan H; İlhan O; Beksaç M; Gürman G; Özcan M
Turk J Haematol; 2017 Mar; 34(1):16-26. PubMed ID: 27094579
[TBL] [Abstract][Full Text] [Related]
5. Outcomes Following Bone Marrow Transplantation in Children With Accelerated Phase or Blast Crisis Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors.
Shulman DS; Lee MA; Lehmann LE; Margossian SP
J Pediatr Hematol Oncol; 2016 Nov; 38(8):610-614. PubMed ID: 27403776
[TBL] [Abstract][Full Text] [Related]
6. Management of chronic myeloid leukemia in blast crisis.
Saußele S; Silver RT
Ann Hematol; 2015 Apr; 94 Suppl 2():S159-65. PubMed ID: 25814082
[TBL] [Abstract][Full Text] [Related]
7. Impact of frontline treatment approach on outcomes of myeloid blast phase CML.
Saxena K; Jabbour E; Issa G; Sasaki K; Ravandi F; Maiti A; Daver N; Kadia T; DiNardo CD; Konopleva M; Cortes JE; Yilmaz M; Chien K; Pierce S; Kantarjian H; Short NJ
J Hematol Oncol; 2021 Jun; 14(1):94. PubMed ID: 34130720
[TBL] [Abstract][Full Text] [Related]
8. Blast and accelerated phase CML: room for improvement.
How J; Venkataraman V; Hobbs GS
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):122-128. PubMed ID: 34889372
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.
Nair AP; Barnett MJ; Broady RC; Hogge DE; Song KW; Toze CL; Nantel SH; Power MM; Sutherland HJ; Nevill TJ; Abou Mourad Y; Narayanan S; Gerrie AS; Forrest DL
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1437-44. PubMed ID: 25865648
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.
Gratwohl A; Pfirrmann M; Zander A; Kröger N; Beelen D; Novotny J; Nerl C; Scheid C; Spiekermann K; Mayer J; Sayer HG; Falge C; Bunjes D; Döhner H; Ganser A; Schmidt-Wolf I; Schwerdtfeger R; Baurmann H; Kuse R; Schmitz N; Wehmeier A; Fischer JT; Ho AD; Wilhelm M; Goebeler ME; Lindemann HW; Bormann M; Hertenstein B; Schlimok G; Baerlocher GM; Aul C; Pfreundschuh M; Fabian M; Staib P; Edinger M; Schatz M; Fauser A; Arnold R; Kindler T; Wulf G; Rosselet A; Hellmann A; Schäfer E; Prümmer O; Schenk M; Hasford J; Heimpel H; Hossfeld DK; Kolb HJ; Büsche G; Haferlach C; Schnittger S; Müller MC; Reiter A; Berger U; Saußele S; Hochhaus A; Hehlmann R; ;
Leukemia; 2016 Mar; 30(3):562-9. PubMed ID: 26464170
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia.
Senapati J; Jabbour E; Kantarjian H; Short NJ
Leukemia; 2023 Jan; 37(1):5-17. PubMed ID: 36309558
[TBL] [Abstract][Full Text] [Related]
12. How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.
Perrone S; Massaro F; Alimena G; Breccia M
Expert Opin Pharmacother; 2016 Aug; 17(11):1517-26. PubMed ID: 27231757
[TBL] [Abstract][Full Text] [Related]
13. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Oyekunle A; Zander AR; Binder M; Ayuk F; Zabelina T; Christopeit M; Stübig T; Alchalby H; Schafhausen P; Lellek H; Wolschke C; Müller I; Bacher U; Kröger N
Ann Hematol; 2013 Apr; 92(4):487-96. PubMed ID: 23250623
[TBL] [Abstract][Full Text] [Related]
14. Chronic myeloid leukemia-transplantation in the tyrosine kinase era.
Innes AJ; Apperley JF
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1037-53. PubMed ID: 25459178
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.
Kondo T; Nagamura-Inoue T; Tojo A; Nagamura F; Uchida N; Nakamae H; Fukuda T; Mori T; Yano S; Kurokawa M; Ueno H; Kanamori H; Hashimoto H; Onizuka M; Takanashi M; Ichinohe T; Atsuta Y; Ohashi K
Am J Hematol; 2017 Sep; 92(9):902-908. PubMed ID: 28543934
[TBL] [Abstract][Full Text] [Related]
17. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
Wright MP; Shepherd JD; Barnett MJ; Nantel SH; Sutherland HJ; Toze CL; Hogge DE; Nevill TJ; Song KW; Abou Mourad YR; Narayanan S; Power MM; Smith CA; Forrest DL
Biol Blood Marrow Transplant; 2010 May; 16(5):639-46. PubMed ID: 20005967
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities.
Fernandez HF; Kharfan-Dabaja MA
Cancer Control; 2009 Apr; 16(2):153-7. PubMed ID: 19337201
[TBL] [Abstract][Full Text] [Related]
19. Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Oyekunle A; Klyuchnikov E; Ocheni S; Kröger N; Zander AR; Baccarani M; Bacher U
Acta Haematol; 2011; 126(1):30-9. PubMed ID: 21411987
[TBL] [Abstract][Full Text] [Related]
20. Initial treatment for patients with CML.
Goldman JM
Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
